This study is trying to develop a computational model to find out which patients are likely to benefit from immune therapy
- Conditions
- Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2022/11/047205
- Lead Sponsor
- Kerala Startup Mission
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Non small cell carcinoma lung of any histology who have received treatment with immune checkpoint inhibitor therapy between 2017-2021.
2. Patients should have taken regular treatment as per prescribed protocol for at least 3 months or till first radiological response assessment by iRESIST, whichever is later.
3. Drug treatments include Pembrolizumab/Nivolumab/Durvalumab/Atezolizumab either in combination with chemotherapy or as single agents.
4. Stage IV or recurrent disease.
5. Any line of treatment is included
6. Combination with radiation is included
7. Hematoxylin â?? Eosin slide with/without corresponding FFPE block of tumor biopsy tissue is available.
8. Clinical record of response to ICI therapy is available.
1. Documented infectious pneumonia during first 3 months of therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is development of computational model that predicts responders to immune checkpoint inhibitors with 80% sensitivity.Timepoint: Assessment of response will be at 3 months of starting ICI therapy in retrospective cohort.
- Secondary Outcome Measures
Name Time Method ilTimepoint: NA